Cargando…
Choroidal neovascularization secondary to tuberculosis: Presentation and management()
PURPOSE: While there are many known etiologies of choroidal neovascularization (CNV), tuberculosis is not a well-known causative agent. In this case series, we highlight CNV occurring secondary to tuberculous chorioretinitis, its presentation, and its management. OBSERVATIONS: We retrospectively rev...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5758031/ https://www.ncbi.nlm.nih.gov/pubmed/29503964 http://dx.doi.org/10.1016/j.ajoc.2016.12.025 |
_version_ | 1783290935440834560 |
---|---|
author | Lee Kim, Esther Rodger, Damien C. Rao, Narsing A. |
author_facet | Lee Kim, Esther Rodger, Damien C. Rao, Narsing A. |
author_sort | Lee Kim, Esther |
collection | PubMed |
description | PURPOSE: While there are many known etiologies of choroidal neovascularization (CNV), tuberculosis is not a well-known causative agent. In this case series, we highlight CNV occurring secondary to tuberculous chorioretinitis, its presentation, and its management. OBSERVATIONS: We retrospectively reviewed the charts and imaging of four patients who presented with presumed tuberculous chorioretinitis and CNV. Three of these patients had signs of intraocular inflammation and were also found to have active macular CNV. The one remaining patient had chorioretinal scars from prior posterior uveitis and previously treated macular CNV membranes. The three patients with active disease were started on anti-tuberculosis medications and oral corticosteroids, and they also received intravitreal anti-vascular endothelial growth factor (VEGF) injections as needed for the CNV. There was a significant improvement in the clinical course of all three patients with active disease—the intraocular inflammation subsided, and CNV recurrences were mitigated. Upon completion of systemic treatment, all patients have remained quiescent. CONCLUSIONS AND IMPORTANCE: Our findings demonstrate that CNV may occur in the course of tuberculous chorioretinitis with marked loss of vision, and management with anti-tuberculosis medications, oral corticosteroids, and intravitreal anti-VEGF injections results in notable improvement in their clinical course. |
format | Online Article Text |
id | pubmed-5758031 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-57580312018-03-02 Choroidal neovascularization secondary to tuberculosis: Presentation and management() Lee Kim, Esther Rodger, Damien C. Rao, Narsing A. Am J Ophthalmol Case Rep Case report PURPOSE: While there are many known etiologies of choroidal neovascularization (CNV), tuberculosis is not a well-known causative agent. In this case series, we highlight CNV occurring secondary to tuberculous chorioretinitis, its presentation, and its management. OBSERVATIONS: We retrospectively reviewed the charts and imaging of four patients who presented with presumed tuberculous chorioretinitis and CNV. Three of these patients had signs of intraocular inflammation and were also found to have active macular CNV. The one remaining patient had chorioretinal scars from prior posterior uveitis and previously treated macular CNV membranes. The three patients with active disease were started on anti-tuberculosis medications and oral corticosteroids, and they also received intravitreal anti-vascular endothelial growth factor (VEGF) injections as needed for the CNV. There was a significant improvement in the clinical course of all three patients with active disease—the intraocular inflammation subsided, and CNV recurrences were mitigated. Upon completion of systemic treatment, all patients have remained quiescent. CONCLUSIONS AND IMPORTANCE: Our findings demonstrate that CNV may occur in the course of tuberculous chorioretinitis with marked loss of vision, and management with anti-tuberculosis medications, oral corticosteroids, and intravitreal anti-VEGF injections results in notable improvement in their clinical course. Elsevier 2017-01-06 /pmc/articles/PMC5758031/ /pubmed/29503964 http://dx.doi.org/10.1016/j.ajoc.2016.12.025 Text en © 2017 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Case report Lee Kim, Esther Rodger, Damien C. Rao, Narsing A. Choroidal neovascularization secondary to tuberculosis: Presentation and management() |
title | Choroidal neovascularization secondary to tuberculosis: Presentation and management() |
title_full | Choroidal neovascularization secondary to tuberculosis: Presentation and management() |
title_fullStr | Choroidal neovascularization secondary to tuberculosis: Presentation and management() |
title_full_unstemmed | Choroidal neovascularization secondary to tuberculosis: Presentation and management() |
title_short | Choroidal neovascularization secondary to tuberculosis: Presentation and management() |
title_sort | choroidal neovascularization secondary to tuberculosis: presentation and management() |
topic | Case report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5758031/ https://www.ncbi.nlm.nih.gov/pubmed/29503964 http://dx.doi.org/10.1016/j.ajoc.2016.12.025 |
work_keys_str_mv | AT leekimesther choroidalneovascularizationsecondarytotuberculosispresentationandmanagement AT rodgerdamienc choroidalneovascularizationsecondarytotuberculosispresentationandmanagement AT raonarsinga choroidalneovascularizationsecondarytotuberculosispresentationandmanagement |